Experiment 67149
Worktypes
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | ORAL |
| Organism | Prunus africana (ROSACEAE) |
| Citation | ISHANI,A: MACDONALD,R: NELSON,D: RUTKS,I: WILT,TJ:. (2000). PYGEUM AFRICANUM FOR THE TREATMENT OF PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA:A SYSTEMATIC REVIEW AND QUANTITATIVE META-ANALYSIS.. 109(8) |
| Amount utilized | |
| Compound isolated | |
| Disease | A TOTAL OF 18 RANDOMIZED CONTROLLED TRIALS INVOLVING 1562 MEN MET THE INCLUSION CRITERIA AND WERE ANALYZED. MANY STUDIES DID NOT REPORT RESULTS IN A METHOD THAT PERMITTED META-ANALYSIS. ONLY 1 OF THE STUDIES REPORTED A METHOD OF TREATMENT ALLOCATION CONCEALMENT, ALTHOUGH 17 WERE DOUBLE-BLINDED. THE MEAN STUDY DURATION WAS 64 DAYS (RANGE 30 TO 122). COMPARED WITH PLACEBO IN 6 STUDIES, P.AFRICANUM PROVIDED A MODERATELY LARGE IMPROVEMENT IN THE COMBINED OUTCOME OF UROLOGIC SYMPTOMS AND FLOW MEASURES AS ASSESSED BY AN EFFECT SIZE DEFINED BY THE DIFFERENCE OF THE MEAN CHANGE FOR EACH OUTCOME DIVIDED BY THE POOLED STANDARD DEVIATION FOR EACH OUTCOME (-0.8SD[95% CONFIDENCE INTERVAL(CI):-1.4 TO -0.3]). SUMMARY ESTIMATES OF INDIVIDUAL OUTCOMES WERE ALSO IMPROVED BY P.AFRICANUM. MEN WERE MORE THAN TWICE AS LIKELY TO REPORT AN IMPROVEMENT IN OVERALL SYMPTOMS. NOCTURIA WAS REDUCED BY 19% AND RESIDUAL URINE VOLUME BY 24%; PEAK URINE FLOW WAS INCREASED BY 23%. ADVERSE EFFECTS DUE TO P. AFRICANUM WERE MILD AND SIMILAR TO PLACEBO. THE OVERALL DROP OUT RATE WAS 12% AND WAS SIMILAR FOR P. AFRICANUM (13%), PLACEBO(11%), AND OTHER CONTROLS(8%;P=0.4 VERSUS PLACEBO AND P=0.5 VERSUS OTHER CONTROLS). THE EVIDENCE SUGGESTS THAT P. AFRICANUM MODESTLY, BUT SIGNIFICANTLY, IMPROVES UROLOGIC SYMPTOMS AND FLOW MEASURES. FURTHER RESEARCH IS NEEDED USING STANDARDIZED PREPARATIONS OF P. AFRICANUM TO DETERMINE ITS LONG-TERM EFFECTIVENESS AND ABILITY TO PREVENT COMPLICATIONS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA. |
| Dose amount | VAR |
| Number | 2 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Dose expression | DOSE |
| Extract | CHCL3 EXT |
| Gender | MALE |